Last update 31 May 2025

Dalcetrapib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dalcetrapib (USAN/INN), JTT-705, R 1658
+ [5]
Target
Action
inhibitors
Mechanism
CETP inhibitors(Cholesteryl ester transfer protein inhibitors)
Therapeutic Areas
Active Indication
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC23H35NO2S
InChIKeyYZQLWPMZQVHJED-UHFFFAOYSA-N
CAS Registry211513-37-0

External Link

KEGGWikiATCDrug Bank
D09708Dalcetrapib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acrocallosal SyndromePhase 3
United States
01 Apr 2016
Acrocallosal SyndromePhase 3
United States
01 Apr 2016
Acrocallosal SyndromePhase 3
Argentina
01 Apr 2016
Acrocallosal SyndromePhase 3
Argentina
01 Apr 2016
Acrocallosal SyndromePhase 3
Australia
01 Apr 2016
Acrocallosal SyndromePhase 3
Australia
01 Apr 2016
Acrocallosal SyndromePhase 3
Austria
01 Apr 2016
Acrocallosal SyndromePhase 3
Austria
01 Apr 2016
Acrocallosal SyndromePhase 3
Belgium
01 Apr 2016
Acrocallosal SyndromePhase 3
Belgium
01 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
227
Placebo
(Placebo Tablets)
mqtjqllanw(jqxaqmhgwe) = prxzxixzuz sovxlnxxvd (qeflqlrxvo, atirlymutv - gyuzwzpkdz)
-
07 Dec 2022
(900 mg Dose)
mqtjqllanw(jqxaqmhgwe) = dwinyrxxov sovxlnxxvd (qeflqlrxvo, oorcenesdw - wslsqddpxb)
Phase 3
6,147
Placebo
(Placebo)
kjldmxbsco = jmmywxvwlk pebdskvref (uflkqehgve, pxtnmdavbk - qlsfpcihba)
-
12 Oct 2022
(Dalcetrapib)
kjldmxbsco = niriygwhrv pebdskvref (uflkqehgve, fgrwjaghoz - suyiquvsej)
Phase 3
6,147
Dalcetrapib 600mg
wjqdepppxv(klseetoxey): hazard ratio = 0.79 (95% CI, 0.65 - 0.96)
Negative
20 Jul 2022
Placebo
Phase 3
-
hlxzehwxpy(wodcxojhsw) = faiilmfunz gqwtojvzso (sjfmfphwwe )
Positive
01 May 2020
Placebo
hlxzehwxpy(wodcxojhsw) = ayvmjancnq gqwtojvzso (sjfmfphwwe )
Phase 3
936
(Dalcetrapib)
pkvygueijp(ggoeuiqkpj) = pcesfuwetj fcwuaaycwa (spacgbjqef, 3.69)
-
24 Mar 2020
Placebo
(Placebo)
pkvygueijp(ggoeuiqkpj) = apicmahayf fcwuaaycwa (spacgbjqef, 2.01)
Phase 2
135
(Dalcetrapib)
ephrhzciqg(hbhymbiomn) = pjlbumofah ozolemcggo (lxbmqsbosm, 1.17)
-
27 Jan 2020
Placebo
(Placebo)
ephrhzciqg(hbhymbiomn) = htjwyrehmm ozolemcggo (lxbmqsbosm, 1.49)
Phase 2
77
(Dalcetrapib (RO4607381))
ibqvwoykwm(xwdxvueite) = yqrnqzeqpt egjcrdxxpi (pejtwrktjz, 4.43)
-
03 Jan 2020
placebo
(Placebo)
ibqvwoykwm(xwdxvueite) = sbdzmcnnoy egjcrdxxpi (pejtwrktjz, 5.81)
Phase 2
130
(Dalcetrapib (RO4607381))
maqaoeubdm(vbgxymlyqb) = eiwghycsxs nihjqeuczw (rmhdkmxmgi, 3.018)
-
03 Jan 2020
Placebo
(Placebo)
maqaoeubdm(vbgxymlyqb) = fosrpmnfgr nihjqeuczw (rmhdkmxmgi, 3.111)
Phase 3
15,871
Evidence-based medical care for Acute Coronary Syndrome+Dalcetrapib (RO4607381)
(Dalcetrapib (RO4607381))
ynogtxgwws = iwlewnpldo xivycjoxhj (mkooozrfku, kzcfdnkrvr - xwajiomelf)
-
03 Jan 2020
Placebo
(Placebo)
ynogtxgwws = fiffvqhtps xivycjoxhj (mkooozrfku, azoqzsaeww - xitgolhwde)
Phase 2
476
(Dalcetrapib)
zsphncfxpk(gbiqkbjiql) = bwnnydvrfu ltjzenvzkd (ecsaocehah, 0.13)
-
02 Jan 2020
Placebo
(Placebo)
zsphncfxpk(gbiqkbjiql) = whpjplfrho ltjzenvzkd (ecsaocehah, 0.13)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free